DC Field | Value | Language |
dc.contributor.author | Costiuc, Maria | |
dc.date.accessioned | 2020-07-07T04:37:08Z | |
dc.date.available | 2020-07-07T04:37:08Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | COSTIUC, Maria. Treatment compliance in essential hypertension. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 72-73. | en_US |
dc.identifier.isbn | 978-9975-3028-3-8. | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11028 | |
dc.description | Internal Medicine, Cardiology Discipline, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctors, May 12-14, 2016 | en_US |
dc.description.abstract | Introduction: Hypertension, the main risk factor responsible for 13% global mortality, is poorly
controled worldwide. Acces to treatment and compliance to it are the key factors in controlinghypertension. The purpose of the study is to assess treatment compliance in patients with essential
arterial hypertension.
Materials and methods: The prospective study included 23 patients with essential hypertension
hospitalized in the Institute of Cardiology, the report women:men 1:1, mid age 64±7,4. The assessment
involved the investigation using Hill-Bone questionnaire, including 3 important behavioral domains of
hight blood presure treatment: sodium intake, appointment keeping and medication taking. Rezulting
values placed within 14-56 points, with an average of 25,6 points.
Discussion results: Analysis of the obtained data showed an average score of 22,26 points, with
similar results for both female and male (22.2:22.3points), close to the average result. Noncompliant
were 6 (26%) patients, of which 4 women (17.4%) and only 2 men (8.6%), with a score highter than the
averege values. Compliance was proved similar in all 3 behavioral domains.
Conclusion: Compliance evaluation in patients with essential hypertension showed that 26%
patients remain noncompliant to the treatment. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | Hypertension | en_US |
dc.subject | compliance | en_US |
dc.subject | Hill-Bone | en_US |
dc.title | Treatment compliance in essential hypertension | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2016
|